Organon & Co.
OGN Healthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OGN
Organon & Co. (OGN) P/E ratio
As of 16 October 2026, Organon & Co. (OGN) trades at a P/E ratio of 17.4×. Over the past ten years it has ranged from 2.8× (May 2025) to 17.5× (October 2026); the current reading is higher than 99% of that period. That is below the Drug Manufacturers General industry median of 24.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 10.0× | 123.60% |
| FY2024 | 4.5× | 21.71% |
| FY2023 | 3.7× | (53.07%) |
| FY2022 | 7.8× | 36.48% |
| FY2021 | 5.7× | 25.89% |
| FY2020 | 4.5× | 0.00% |
| FY2019 | 4.5× | 0.00% |
| FY2018 | 4.5× | 0.00% |
| FY2017 | 4.5× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 17.1× | 168.96% |
| Mar 2026 | 6.4× | (36.01%) |
| Dec 2025 | 10.0× | 79.96% |
| Sep 2025 | 5.5× | 54.92% |
| 22 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AMRN Amarin Corporation PLC compare | n/m |
| GRFS Grifols, S.A. compare | 8.5× |
| NVO Novo Nordisk A/S compare | 9.5× |
| BMY Bristol Myers Squibb Company compare | 13.2× |
| GSK GSK PLC Sponsored ADR compare | 15.4× |
| OGN Organon & Co. | 17.4× |
| SNY Sanofi compare | 21.3× |
| PFE Pfizer Inc. compare | 38.9× |
| BIIB Biogen Inc. compare | 41.0× |
| Drug Manufacturers General industry median | 24.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)